

Quality-Data Code Submission Error Report 2nd Quarter 2011 Physician Quality Reporting System

Report Date: 10/24/2011

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

QDC Submission Attempts:

- Total QDCs Reported - The number of instances where a TIN/NPI submitted a QDC for that measure.
- Total Valid QDCs Reported on Eligible Cases - The number of instances where a TIN/NPI submitted a valid QDC for that measure.
- % Valid – Percentage of Total Valid QDCs Reported divided by Total QDCs Reported on Eligible Cases.
- Total QDCs Reported on Eligible Cases – Number of valid or invalid QDCs reported on eligible cases meeting the measure's denominator requirements.

Denominator Mismatch:

- Measure Reported with Incorrect Age and/or Gender - The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.
- Incorrect Diagnosis and/or HCPCS - The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
- Measure Reported on an Instance with a Missing CPT Code - The number of occurrences of QDC reporting when there are no CPT codes for billable services on the claim associated with the denominator requirements for the measure.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #1-Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus as an example, we find the following information as we read across each column:

363,461 QDC submissions were received for this measure, 287,318 of which were considered valid. Therefore, the Valid Submission Rate is 79.05%. There were a total of 287,688 QDCs reported on eligible cases. The rest of the columns explain reasons for invalid submissions for measure #1. We see that 62,341 (17.15%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 71,585 (19.70%) submissions were for patient encounters and/or diagnoses that are not listed in the denominator; 1,230 (0.34%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, TIN/NPI.

Analysis Findings Include:

Quality-Data Code Submission Error Report by Individual Measure (Claims)

1. The top 5 measures with the highest percentage of valid QDCs codes submitted were:
 - #203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control (98.88%)
 - #202 Ischemic Vascular Disease (IVD): Complete Lipid Profile (98.46%)
 - #204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic (98.33%)
 - #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (97.99%)
 - #147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy (97.61%)
2. The 5 measures with the lowest percentage of Valid QDCs submitted (with at least 1 eligible instance) were:
 - #188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (0.08%)
 - #66 Appropriate Testing for Children with Pharyngitis (0.34%)
 - #65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (0.36%)
 - #232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (0.40%)
 - #231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (0.89%)

3. The 5 measures with the highest rate of HCPCS/diagnosis errors were:

#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear (99.61%)

#66 Appropriate Testing for Children with Pharyngitis (94.87%)

#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (94.64%)

#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days (93.49%)

#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (93.20%)

4. The 5 measures with the highest rate of patient age/gender errors were:

#66 Appropriate Testing for Children with Pharyngitis (99.66%)

#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use (99.64%)

#94 Otitis Media with Effusion (OME): Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility (99.55%)

#231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting (94.85%)

#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting (87.16%)

Physician Quality Reporting - Quality-Data Code Submission Error Report by Individual Measure (Claims)

Report Includes Claims Data for Services Provided from January 1, 2011 through June 30, 2011 and Processed by June 24, 2011

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#1 Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	363,461	287,318	79.05%	287,688	62,341	17.15%	71,585	19.70%	1,230	0.34%
#2 Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	333,302	264,165	79.26%	264,681	54,290	16.29%	65,071	19.52%	1,134	0.34%
#3 Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	385,072	269,464	69.98%	277,693	73,447	19.07%	102,795	26.70%	1,357	0.35%
#6 Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD	510,134	470,225	92.18%	470,225	0	0.00%	38,514	7.55%	1,221	0.24%
#9 Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	12,241	9,195	75.12%	9,195	0	0.00%	2,773	22.65%	239	1.95%
#10 Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	233,358	197,329	84.56%	209,707	0	0.00%	21,624	9.27%	1,255	0.54%
#12 Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	711,767	592,304	83.22%	592,755	0	0.00%	117,820	16.55%	808	0.11%
#14 Age-Related Macular Degeneration (AMD): Dilated Macular Examination	667,134	641,994	96.23%	642,244	734	0.11%	23,773	3.56%	1,002	0.15%
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	212,667	178,103	83.75%	178,142	0	0.00%	34,030	16.00%	393	0.18%
#19 Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	152,596	91,512	59.97%	114,067	0	0.00%	38,179	25.02%	241	0.16%
#20 Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	69,123	52,184	75.49%	52,184	6	0.01%	16,403	23.73%	536	0.78%
#21 Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	110,560	85,778	77.59%	85,778	10	0.01%	23,996	21.70%	786	0.71%
#22 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	105,804	57,687	54.52%	73,802	11	0.01%	31,072	29.37%	930	0.88%
#23 Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	90,901	70,498	77.55%	70,498	7	0.01%	19,846	21.83%	557	0.61%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on a Missing CPT Code	
					#	%	#	%	#	%
#24 Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	5,842	2,079	35.59%	2,079	37	0.63%	3,211	54.96%	41	0.70%
#28 Aspirin at Arrival for Acute Myocardial Infarction (AMI)	33,068	31,287	94.61%	31,288	0	0.00%	1,662	5.03%	53	0.16%
#30 Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	1,835,600	1,478,592	80.55%	1,484,649	114	0.01%	342,526	18.66%	8,425	0.46%
#31 Stroke and Stroke Rehabilitation: Deep Vein Thrombosis Prophylaxis (DVT) for Ischemic Stroke or Intracranial Hemorrhage	9,297	7,500	80.67%	7,500	0	0.00%	1,714	18.44%	74	0.80%
#32 Stroke and Stroke Rehabilitation: Discharged on Antiplatelet Therapy	12,198	10,561	86.58%	10,561	0	0.00%	1,531	12.55%	93	0.76%
#35 Stroke and Stroke Rehabilitation: Screening for Dysphagia	6,263	4,252	67.89%	4,777	0	0.00%	1,452	23.18%	25	0.40%
#36 Stroke and Stroke Rehabilitation: Consideration of Rehabilitation Services	9,160	7,656	83.58%	7,676	0	0.00%	1,406	15.35%	64	0.70%
#39 Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	277,796	256,678	92.40%	256,678	12,887	4.64%	18,856	6.79%	2,262	0.81%
#40 Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	15,959	798	5.00%	798	176	1.10%	14,649	91.79%	36	0.23%
#41 Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	40,340	32,080	79.52%	32,080	293	0.73%	7,884	19.54%	257	0.64%
#43 Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	13,224	8,844	66.88%	8,846	0	0.00%	4,260	32.21%	118	0.89%
#44 Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	9,198	6,090	66.21%	6,090	0	0.00%	3,005	32.67%	103	1.12%
#45 Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	96,574	22,006	22.79%	27,247	8	0.01%	68,115	70.53%	1,212	1.25%
#46 Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	15,680	2,755	17.57%	5,394	552	3.52%	1,597	10.18%	459	2.93%
#47 Advance Care Plan	544,474	479,770	88.12%	495,806	27,044	4.97%	46,240	8.49%	2,428	0.45%
#48 Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	176,567	156,387	88.57%	156,388	10,977	6.22%	17,873	10.12%	2,306	1.31%
#49 Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	41,266	30,677	74.34%	30,678	1,930	4.68%	10,390	25.18%	77	0.19%
#50 Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	38,495	29,235	75.94%	29,237	1,798	4.67%	9,004	23.39%	139	0.36%
#51 Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	64,643	58,758	90.90%	58,758	0	0.00%	5,680	8.79%	185	0.29%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#52 Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	55,353	42,361	76.53%	51,049	0	0.00%	4,027	7.28%	254	0.46%
#53 Asthma: Pharmacologic Therapy	4,601	1,000	21.73%	1,136	3,348	72.77%	3,018	65.59%	7	0.15%
#54 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	725,768	527,001	72.61%	527,015	8,595	1.18%	196,753	27.11%	1,397	0.19%
#55 12-Lead Electrocardiogram (ECG) Performed for Syncope	717,879	157,619	21.96%	157,619	126,768	17.66%	557,616	77.68%	393	0.05%
#56 Community-Acquired Pneumonia (CAP): Vital Signs	278,632	207,373	74.43%	207,387	5	0.00%	18,835	6.76%	1,094	0.39%
#57 Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	297,677	228,405	76.73%	228,405	5	0.00%	13,908	4.67%	1,123	0.38%
#58 Community-Acquired Pneumonia (CAP): Assessment of Mental Status	270,618	208,643	77.10%	208,658	5	0.00%	10,184	3.76%	974	0.36%
#59 Community-Acquired Pneumonia (CAP): Empiric Antibiotic	193,561	148,222	76.58%	148,222	4	0.00%	7,340	3.79%	780	0.40%
#64 Asthma: Asthma Assessment	2,985	622	20.84%	622	2,303	77.15%	1,939	64.96%	1	0.03%
#65 Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	560	2	0.36%	2	558	99.64%	530	94.64%	0	0.00%
#66 Appropriate Testing for Children with Pharyngitis	585	2	0.34%	2	583	99.66%	555	94.87%	0	0.00%
#67 Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	9,761	9,110	93.33%	9,110	0	0.00%	630	6.45%	20	0.20%
#68 Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	6,245	5,624	90.06%	5,861	0	0.00%	364	5.83%	17	0.27%
#69 Multiple Myeloma: Treatment with Bisphosphonates	8,080	7,693	95.21%	7,693	0	0.00%	371	4.59%	6	0.07%
#70 Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	10,077	9,559	94.86%	9,559	0	0.00%	497	4.93%	21	0.21%
#71 Breast Cancer: Hormonal Therapy for Stage IC-III C Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	47,406	42,539	89.73%	45,689	173	0.36%	1,602	3.38%	102	0.22%
#72 Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	12,989	11,573	89.10%	12,263	0	0.00%	699	5.38%	24	0.18%
#76 Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	132,260	118,057	89.26%	118,058	0	0.00%	13,173	9.96%	1,029	0.78%
#79 End Stage Renal Disease (ESRD): Influenza Immunization in Patients with ESRD	6,690	4,273	63.87%	4,273	0	0.00%	2,288	34.20%	7	0.10%
#84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	1,949	1,731	88.81%	1,780	0	0.00%	161	8.26%	8	0.41%
#85 Hepatitis C: HCV Genotype Testing Prior to Treatment	1,817	1,607	88.44%	1,706	0	0.00%	105	5.78%	6	0.33%
#86 Hepatitis C: Antiviral Treatment Prescribed	1,042	940	90.21%	940	0	0.00%	98	9.40%	4	0.38%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#87 Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	979	851	86.93%	869	0	0.00%	108	11.03%	2	0.20%
#89 Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	1,656	1,419	85.69%	1,422	0	0.00%	230	13.89%	3	0.18%
#90 Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	266	160	60.15%	179	0	0.00%	80	30.08%	2	0.75%
#91 Acute Otitis Externa (AOE): Topical Therapy	2,722	2,521	92.62%	2,521	0	0.00%	183	6.72%	18	0.66%
#92 Acute Otitis Externa (AOE): Pain Assessment	3,881	2,989	77.02%	2,990	0	0.00%	864	22.26%	21	0.54%
#93 Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	2,092	1,942	92.83%	1,946	0	0.00%	133	6.36%	13	0.62%
#94 Otitis Media with Effusion (OME): Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	220	0	0.00%	0	219	99.55%	184	83.64%	0	0.00%
#99 Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	27,685	15,224	54.99%	15,230	0	0.00%	12,216	44.12%	102	0.37%
#100 Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	26,503	9,130	34.45%	9,133	0	0.00%	16,887	63.72%	90	0.34%
#102 Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	3,810	1,967	51.63%	2,052	0	0.00%	1,707	44.80%	45	1.18%
#104 Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	2,615	1,914	73.19%	1,979	0	0.00%	586	22.41%	50	1.91%
#105 Prostate Cancer: Three-Dimensional (3D) Radiotherapy	3,057	2,315	75.73%	2,400	0	0.00%	580	18.97%	58	1.90%
#106 Major Depressive Disorder (MDD): Diagnostic Evaluation	8,923	5,551	62.21%	5,551	0	0.00%	3,225	36.14%	81	0.91%
#107 Major Depressive Disorder (MDD): Suicide Risk Assessment	21,685	13,663	63.01%	13,663	0	0.00%	7,758	35.78%	153	0.71%
#108 Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	23,231	22,223	95.66%	22,233	0	0.00%	940	4.05%	54	0.23%
#109 Osteoarthritis (OA): Function and Pain Assessment	50,303	39,982	79.48%	39,984	0	0.00%	9,617	19.12%	569	1.13%
#110 Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old	539,160	517,703	96.02%	517,703	7,387	1.37%	18,920	3.51%	2,537	0.47%
#111 Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	572,934	539,047	94.09%	539,249	17,118	2.99%	29,639	5.17%	4,046	0.71%
#112 Preventive Care and Screening: Screening Mammography	127,570	87,561	68.64%	87,588	34,012	26.66%	34,625	27.14%	5,357	4.20%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#113 Preventive Care and Screening: Colorectal Cancer Screening	323,489	257,903	79.73%	258,040	54,980	17.00%	59,435	18.37%	6,014	1.86%
#116 Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	567	143	25.22%	143	370	65.26%	402	70.90%	10	1.76%
#117 Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	430,275	275,554	64.04%	276,381	143,268	33.30%	147,385	34.25%	661	0.15%
#119 Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	67,625	53,352	78.89%	53,366	12,131	17.94%	12,474	18.45%	402	0.59%
#121 Chronic Kidney Disease (CKD): Laboratory Testing (Calcium, Phosphorus, Intact Parathyroid Hormone (iPTH) and Lipid Profile)	13,147	7,797	59.31%	7,798	0	0.00%	5,278	40.15%	53	0.40%
#122 Chronic Kidney Disease (CKD): Blood Pressure Management	80,896	12,888	15.93%	14,300	1	0.00%	66,237	81.88%	46	0.06%
#123 Chronic Kidney Disease (CKD): Plan of Care – Elevated Hemoglobin for Patients Receiving Erythropoiesis-Stimulating Agents (ESA)	16,461	8,759	53.21%	9,794	1	0.01%	6,632	40.29%	11	0.07%
#124 Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	6,536,203	6,213,520	95.06%	6,213,520	0	0.00%	286,984	4.39%	35,699	0.55%
#126 Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	93,838	83,166	88.63%	83,166	0	0.00%	10,226	10.90%	409	0.44%
#127 Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	71,264	66,055	92.69%	66,055	0	0.00%	4,857	6.82%	319	0.45%
#128 Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	453,815	431,842	95.16%	431,842	1	0.00%	18,768	4.14%	3,205	0.71%
#130 Documentation of Current Medications in the Medical Record	3,307,357	3,160,424	95.56%	3,160,424	25	0.00%	128,667	3.89%	18,266	0.55%
#131 Pain Assessment Prior to Initiation of Patient Therapy and Follow-Up	275,651	209,678	76.07%	209,678	5	0.00%	58,992	21.40%	6,981	2.53%
#134 Screening for Clinical Depression and Follow-Up Plan	13,265	9,442	71.18%	9,442	0	0.00%	3,320	25.03%	503	3.79%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	2,231	843	37.79%	843	0	0.00%	1,351	60.56%	0	0.00%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	430,678	415,833	96.55%	417,556	397	0.09%	12,438	2.89%	641	0.15%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	178,248	154,153	86.48%	162,599	0	0.00%	15,343	8.61%	243	0.14%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	65,018	43,288	66.58%	43,299	1	0.00%	21,208	32.62%	434	0.67%
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	432,916	406,034	93.79%	406,144	0	0.00%	23,577	5.45%	3,195	0.74%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	950,602	918,624	96.64%	921,956	0	0.00%	25,080	2.64%	3,192	0.34%
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	85,960	83,905	97.61%	83,908	0	0.00%	1,766	2.05%	285	0.33%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	8,368	5,462	65.27%	5,462	0	0.00%	2,876	34.37%	12	0.14%
#154 Falls: Risk Assessment	244,824	189,096	77.24%	218,797	18,989	7.76%	23,664	9.67%	2,363	0.97%
#155 Falls: Plan of Care	50,908	27,079	53.19%	27,080	0	0.00%	0	0.00%	1,841	3.62%
#156 Oncology: Radiation Dose Limits to Normal Tissues	1,153	978	84.82%	978	0	0.00%	163	14.14%	8	0.69%
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	409	274	66.99%	274	0	0.00%	132	32.27%	1	0.24%
#158 Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	2,126	2,072	97.46%	2,072	0	0.00%	47	2.21%	7	0.33%
#163 Diabetes Mellitus: Foot Exam	91,990	60,359	65.61%	60,361	25,095	27.28%	28,481	30.96%	551	0.60%
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	2,128	1,908	89.66%	1,908	2	0.09%	203	9.54%	17	0.80%
#173 Preventive Care and Screening: Unhealthy Alcohol Use – Screening	264,914	256,867	96.96%	256,868	0	0.00%	7,017	2.65%	1,029	0.39%
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	0	0	0.00%	0	0	0.00%	0	0.00%	0	0.00%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	8,984	7,999	89.04%	8,779	0	0.00%	187	2.08%	16	0.18%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	9,386	9,157	97.56%	9,157	0	0.00%	204	2.17%	22	0.23%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	10,413	9,914	95.21%	9,914	0	0.00%	468	4.49%	22	0.21%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	6,264	6,138	97.99%	6,154	0	0.00%	101	1.61%	9	0.14%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	6,429	6,153	95.71%	6,315	0	0.00%	103	1.60%	11	0.17%
#181 Elder Maltreatment Screen and Follow-Up Plan	1,530	711	46.47%	711	87	5.69%	778	50.85%	41	2.68%
#182 Functional Outcome Assessment in Chiropractic Care	84,302	80,594	95.60%	80,594	5	0.01%	3,270	3.88%	438	0.52%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1,075	998	92.84%	998	0	0.00%	76	7.07%	1	0.09%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	1,024	949	92.68%	951	0	0.00%	72	7.03%	1	0.10%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.

Measure	QDC Submission Attempts				Denominator Mismatch ^c					
	Total QDCs Reported ^a	Total Valid QDCs Reported on Eligible Cases ^b	% Valid	Total QDCs Reported on Eligible Cases	Measure Reported with Incorrect Age and/or Gender ^d		Incorrect DX and/or HCPCS		Measure Reported on an Instance with a Missing CPT Code	
					#	%	#	%	#	%
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	20,097	17,276	85.96%	17,276	0	0.00%	2,623	13.05%	50	0.25%
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	1,395	904	64.80%	904	0	0.00%	479	34.34%	0	0.00%
#188 Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	1,290	1	0.08%	1	0	0.00%	1,285	99.61%	0	0.00%
#189 Referral for Otologic Evaluation for Patients with History of Active Drainage From the Ear Within the Previous 90 Days	476	24	5.04%	25	0	0.00%	445	93.49%	1	0.21%
#190 Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	1,485	1,215	81.82%	1,230	0	0.00%	249	16.77%	6	0.40%
#193 Perioperative Temperature Management	1,145,691	1,073,982	93.74%	1,103,931	0	0.00%	38,398	3.35%	3,362	0.29%
#194 Oncology: Cancer Stage Documented	51,127	47,478	92.86%	47,504	0	0.00%	3,424	6.70%	179	0.35%
#195 Radiology: Stenosis Measurement in Carotid Imaging Studies	257,154	239,404	93.10%	239,731	0	0.00%	15,980	6.21%	1,443	0.56%
#201 Ischemic Vascular Disease (IVD): Blood Pressure Management Control	118,819	110,085	92.65%	116,664	0	0.00%	1,773	1.49%	354	0.30%
#202 Ischemic Vascular Disease (IVD): Complete Lipid Profile	113,569	111,824	98.46%	111,824	0	0.00%	1,483	1.31%	246	0.22%
#203 Ischemic Vascular Disease (IVD): Low Density Lipoprotein (LDL-C) Control	78,291	77,417	98.88%	77,417	0	0.00%	677	0.86%	183	0.23%
#204 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	120,697	118,676	98.33%	118,676	0	0.00%	1,668	1.38%	325	0.27%
#225 Radiology: Reminder System for Mammograms	418,122	28,912	6.91%	28,912	489	0.12%	380,657	91.04%	8,410	2.01%
#226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	1,369,505	1,327,848	96.96%	1,328,529	5	0.00%	35,730	2.61%	5,246	0.38%
#231 Asthma: Tobacco Use: Screening - Ambulatory Care Setting	12,653	112	0.89%	112	12,002	94.85%	11,741	92.79%	1	0.01%
#232 Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	24,422	97	0.40%	247	21,287	87.16%	22,762	93.20%	1	0.00%
#235 Hypertension (HTN): Plan of Care	40,496	29,314	72.39%	37,105	0	0.00%	3,001	7.41%	344	0.85%
Total	29,810,613	25,558,359	85.74%	25,756,645	736,886	2.47%	3,642,348	12.22%	157,624	0.53%

^a The number of instances where a TIN/NPI or GPRO II submitted a QDC for that measure.

^b The number of instances where a TIN/NPI or GPRO II submitted a valid QDC for that measure.

^c The number of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The number of occurrences of QDC reporting where the QDC does not match the demographic requirements for the measure.

Note: ORDI demonstration participants are excluded from these reports.

Note: GPRO I participants are excluded from this report.